Health Policy

New drug launch prices are still high. ICER's 2026 Launch Price and Access Report finds the median net price for 2025 approvals was about $257,000, and only about one in three new prescriptions was filled within 30 days. #SyenzaNews #MarketAccess #HEOR

ASPE finds Medicaid hospital provider taxes raised employer premiums 1.5 to 1.7 percent, and the 2025 WFTC law is projected to cut them further.

The National Health Council says importing foreign price controls through most favored nation pricing will not serve American patients.

What steps is the FDA taking to accelerate rare disease treatments? The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies. Explore how this could reshape drug development for underserved patient populations. #SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicy

Insulin analogue cost-effectiveness studies for adults with type 1 diabetes mostly point the same way: the newer products usually come out ahead of human insulin. A new systematic review says that headline rests on thinner ground than it looks. The paper, by Shiwa Yaghoubi Bina, Steve Njokuocha and the T1D Economic Evidence Synthesis Group, has been accepted for Value in Health. The version available now is a pre-proof, so figures could still change at copyediting. The World Health Organization funded […]

Ministers, development banks and industry at the World Health Summit argued that health investment returns should be measured in lives saved, jobs and tax revenue, not budget size. #SyenzaNews #HealthEconomics #MarketAccess

At the World Health Summit in Berlin, speakers from the European Commission, Japan, Africa, the Asian Development Bank and industry argued that health is a strategic economic asset, and asked how to persuade finance ministries. #SyenzaNews #HealthEconomics

Health utilities for multiple sclerosis fall with disability, and progressive forms score lowest. A UK cohort of 5,772 patients gives modellers EQ-5D and cost inputs by MS type and EDSS band. #SyenzaNews #MarketAccess

PhRMA has sued HHS and CMS over the GLOBE rule, arguing the agency has no authority to tie Medicare Part B drug payments to the prices paid in 19 other countries. The complaint leans on the major questions doctrine and a statutory ban on quality-adjusted life years. #SyenzaNews #MarketAccess #pharmaceuticals #healthcarepolicy #drugpricing

Halozyme has won a Keytruda SC injunction in the Netherlands, ordering MSD to stop supplying the subcutaneous form of pembrolizumab in eight European markets. The case turned on how the patent's stability test is measured, and the injunction lapses country by country if a national court invalidates its part of EP 2 797 622. #SyenzaNews #oncology #patentlitigation #MarketAccess

US group health plans and issuers must rebuild their public price files under the Transparency in Coverage final rule: quarterly publication, an 11-claim threshold for out-of-network data, a new utilization file and attestation, and consumer phone disclosure from January 2027. #SyenzaNews #MarketAccess #PriceTransparency #HEOR

Rare disease care in Europe is settled in national capitals, not in Brussels. At #EHFG2026, Austria's Claas Röhl, Czechia's Markéta Foldyna Hellová, Italy's Giulia De Ponte and MetabERN's Maurizio Scarpa set out where national policy delivers and where families still do the coordinating. #SyenzaNews